Oligomerix, Inc.

Oligomerix

Headquarters: 1300 Morris Park Ave, Bronx, NY 10461 Founded: Based on NYU research Focus: Tau protein aggregation inhibitors, [Alzheimer's disease](/diseases/alzheimers-disease), neurodegenerative diseases Stage: Clinical-stage biotechnology company Website: [oligomerix.com](https://www.oligomerix.com)

Overview

Oligomerix

Headquarters: 1300 Morris Park Ave, Bronx, NY 10461 Founded: Based on NYU research Focus: Tau protein aggregation inhibitors, [Alzheimer's disease](/diseases/alzheimers-disease), neurodegenerative diseases Stage: Clinical-stage biotechnology company Website: [oligomerix.com](https://www.oligomerix.com)

Overview

Oligomerix is a clinical-stage biotechnology company focused on developing small molecule inhibitors targeting tau protein aggregation for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company was founded based on research from New York University and operates from New York["@oligomerix2026"].

The company's name reflects its scientific focus—targeting protein oligomers, which are toxic aggregated forms of proteins that drive neurodegeneration. Unlike approaches that focus on amyloid plaques, Oligomerix targets the tau protein oligomers that form inside [neurons](/entities/neurons) and propagate between brain regions.

With over 16 years of tau research, Oligomerix has established an innovative upstream approach to treating tauopathies through targeting the root cause of tau pathology["@oligomerix2026a"]. This approach addresses the fundamental mechanism of tau propagation, offering the potential for disease modification rather than just symptomatic treatment.

Company Background

Oligomerix emerged from academic research conducted at New York University, one of the world's leading centers for tau biology research. The company's founding scientists brought decades of experience in protein aggregation mechanisms and drug discovery for neurodegenerative diseases.

Operating from New York provides Oligomerix with access to:

• World-class research institutions (NYU, Columbia, Rockefeller)
• Experienced drug development talent from major pharmaceutical companies
• Strong pharmaceutical industry presence
• NIH-funded research programs
• Clinical trial infrastructure

Scientific Heritage

The company's origins trace to groundbreaking research on tau protein aggregation conducted at NYU's School of Medicine. This research established key mechanistic insights into how tau transitions from a normal, functional protein to toxic oligomeric and fibrillar species.

Clinical Pipeline

OLX-07010 (Lead Program)

OLX-07010 is Oligomerix's lead small molecule drug candidate—a tau self-association inhibitor. This first-in-class therapeutic represents a novel approach to treating tauopathies by directly targeting the oligomerization process that drives pathology propagation[@olx2026].

| Attribute | Value |
|-----------|-------|
| Program | OLX-07010 |
| Mechanism | Tau Self-Association Inhibitor |
| Target | Tau protein oligomers |
| Indication | Alzheimer's disease, PSP |
| Development Stage | Phase 1a clinical trials (first-in-human) |

Therapeutic Areas

• Alzheimer's Disease: The lead indication, representing the most common tauopathy
• Progressive Supranuclear Palsy (PSP): A pure tauopathy providing a well-defined clinical population
• Rare Tauopathies: Additional indications under development including corticobasal degeneration

Pipeline Overview

| Program | Indication | Target | Development Status |
|---------|------------|--------|-------------------|
| OLX-07010 | Alzheimer's Disease | Tau oligomers | Phase 1a (first-in-human) |
| OLX-07010 | Progressive Supranuclear Palsy | Tau oligomers | Preclinical |
| Additional programs | Other tauopathies | Tau | Research/Discovery |

Science and Technology

Tau Biology and Pathology

The tau protein is a microtubule-associated protein primarily expressed in neurons. Under normal conditions, tau stabilizes microtubules, which are essential for cellular transport and neuronal integrity. However, in disease states, tau undergoes pathological transformations that contribute to neurodegeneration[@wang2016].

Normal Tau Function

• Microtubule stabilization: Tau binds to microtubules, promoting their polymerization and stability
• Axonal transport: Facilitates intracellular transport along microtubules
• Neuronal development: Important for neuronal polarization and connectivity
• Synaptic function: Modulates synaptic plasticity and function

Pathological Tau Transformation

In Alzheimer's disease and related tauopathies, the tau protein undergoes pathological changes:

The Tau Oligomer Hypothesis

The "tau oligomer" hypothesis, which forms the scientific foundation for Oligomerix's approach, suggests that soluble tau oligomers are the most toxic species in tauopathies[@tau2020]. This hypothesis has gained significant support from research demonstrating that:

• Oligomers are toxic: Soluble oligomers are more toxic to neurons than insoluble tangles
• Oligomers spread: Tau oligomers propagate between neurons, spreading pathology
• Oligomers appear early: Oligomers appear before tangle formation
• Oligomers correlate with symptoms: Tau oligomer levels correlate better with cognitive decline than tangle burden

• Synaptic dysfunction and loss: Oligomers disrupt synaptic plasticity and cause synapse elimination
• Neuronal death: Direct toxicity leads to neuronal loss
• Spread of pathology: Propagation via neural networks spreads tau pathology
• Microglial activation: Oligomers trigger inflammatory responses

Therapeutic Approach

Oligomerix develops small molecules that target tau oligomers through multiple mechanisms:

Drug Discovery Platform

Oligomerix's drug discovery platform includes:

• High-throughput screening: Identification of initial hit compounds
• Structure-activity relationship (SAR) optimization: Systematic improvement of hit compounds
• In vitro assays: Tau aggregation, oligomerization, and cell-based assays
• Animal models: Transgenic tauopathy mouse models for in vivo validation
• Computational chemistry: Structure-based drug design

Differentiating Factors

Oligomerix's approach offers several key differentiators:

• Intracellular targeting: Small molecules reach intracellular tau where oligomers form
• Oligomer specificity: Targets toxic oligomers specifically, not just total tau
• Oral bioavailability: Small molecules suitable for chronic daily dosing
• Combination potential: Works synergistically with amyloid-targeting approaches
• Upstream intervention: Targets root cause of tau propagation

Clinical Development Strategy

Phase 1a Trial Design

The Phase 1a trial of OLX-07010 is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. This first-in-human study establishes the foundation for subsequent trials in patients.

Key objectives:

• Single ascending dose (SAD) safety assessment
• Multiple ascending dose (MAD) evaluation
• Pharmacokinetic profiling
• Food effect study
• Biomarker development

Patient Populations

Oligomerix is developing OLX-07010 for multiple patient populations:

Alzheimer's Disease (AD)

• Most common neurodegenerative disease
• Significant unmet need for disease-modifying therapies
• [Tau](/proteins/tau) pathology strongly correlates with cognitive decline

• Pure tauopathy with defined pathology
• Faster disease progression than AD
• Well-characterized patient population

Biomarker Strategy

Oligomerix is developing biomarkers to support clinical development:

• Tau PET imaging: Visualization of tau pathology burden
• CSF biomarkers: Tau and phospho-tau levels
• Blood-based biomarkers: Emerging fluid biomarkers for tau
• Cognitive measures: Standardized cognitive assessments

Competitive Landscape

Oligomerix competes in the tau aggregation inhibitor and anti-tau therapy space:

| Company | Drug | Approach | Target | Status |
|---------|------|----------|--------|--------|
| Oligomerix | OLX-07010 | Small molecule | Tau oligomers | Phase 1a |
| Axon Neuroscience | AADvac1 | Vaccine | Tau (phospho) | Phase 2 |
| Biogen/IONIS | BIIB080 | Antisense oligo | Tau mRNA | Phase 1/2 |
| Eli Lilly | Semorinemab | Antibody | Tau antibody | Phase 2 (failed) |
| Roche/Genentech | Gosuranemab | Antibody | Tau antibody | Phase 2/3 |
| ABBV-916 | ABBV-916 | Antibody | Tau antibody | Phase 1 |

Competitive Advantages

Oligomerix believes its small molecule approach offers advantages:

• Oral dosing vs. intravenous antibodies
• Intracellular access to tau oligomers
• Potential for combination with other approaches
• Disease-modifying mechanism addressing tau propagation

Research Platform

Oligomerix maintains a robust discovery platform:

• In vitro assays: Tau aggregation, oligomerization, and cell-based assays
• Cellular models: Induced pluripotent stem cell (iPSC)-derived neurons
• Animal models: Transgenic tauopathy mouse models (P301S, rTg4510)
• Computational chemistry: Structure-based drug design and molecular modeling
• Biomarker development: Patient selection and treatment response markers
• Pharmacology: Dose-response and mechanism-of-action studies

Relevance to Neurodegeneration

Tau pathology is central to several neurodegenerative diseases, making Oligomerix's approach broadly applicable:

Alzheimer's Disease

• Neurofibrillary tangles strongly correlate with cognitive decline
• [Tau](/proteins/tau) spread predicts disease progression patterns
• [Tau](/proteins/tau) PET imaging enables disease staging
• [Tau](/proteins/tau) is now recognized as a key therapeutic target

Other Tauopathies

• Progressive supranuclear palsy: Pure tauopathy with 4R tau pathology
• Corticobasal degeneration: Mixed 3R/4R tau pathology
• Frontotemporal dementia: Various tau subtypes
• Chronic traumatic encephalopathy: Tau pathology from repetitive trauma

Disease Progression Patterns

Tau pathology follows predictable patterns in Alzheimer's, known as the Braak staging system:

Understanding this progression informs therapeutic development and patient selection.

Funding and Partnerships

Oligomerix has advanced through multiple funding sources:

• Venture capital: Series funding from biotech-focused investors
• NIH grants: Grant funding for rare disease research
• Strategic partnerships: Collaborations with larger pharmaceutical companies
• Foundation support: Tau research foundations and disease organizations

Academic Collaborations

Oligomerix maintains active collaborations with:

• New York University (founding institution)
• Other leading tau research centers
• Clinical trial networks

Future Directions

Oligomerix's development priorities include:

Related Pages

• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tauopathies](/entities/tauopathies)
• [Protein Aggregation](/entities/protein-aggregation)
• [Neurodegeneration](/entities/neurodegeneration)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Neurofibrillary Tangles](/entities/neurofibrillary-tangles)
• [Tau Propagation](/entities/tau-propagation)

External Links

• [Oligomerix Website](https://www.oligomerix.com)
• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [Alzheimer's Association](https://www.alz.org)
• [CurePSP Foundation](https://www.curepsp.org)

References